Accretive Wealth Partners LLC Sells 217 Shares of West Pharmaceutical Services, Inc. $WST

Accretive Wealth Partners LLC reduced its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 6.2% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 3,286 shares of the medical instruments supplier’s stock after selling 217 shares during the period. Accretive Wealth Partners LLC’s holdings in West Pharmaceutical Services were worth $719,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT bought a new stake in West Pharmaceutical Services during the 1st quarter worth approximately $25,000. Quarry LP purchased a new position in shares of West Pharmaceutical Services in the 1st quarter worth approximately $27,000. First Horizon Advisors Inc. boosted its stake in shares of West Pharmaceutical Services by 85.0% in the 1st quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 85 shares during the last quarter. Cromwell Holdings LLC boosted its stake in shares of West Pharmaceutical Services by 587.5% in the 2nd quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock worth $48,000 after buying an additional 188 shares during the last quarter. Finally, Brooklyn Investment Group boosted its stake in shares of West Pharmaceutical Services by 83.3% in the 1st quarter. Brooklyn Investment Group now owns 275 shares of the medical instruments supplier’s stock worth $61,000 after buying an additional 125 shares during the last quarter. 93.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on WST shares. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Tuesday, October 14th. Redburn Partners set a $311.00 price objective on West Pharmaceutical Services in a research note on Monday, September 15th. UBS Group upped their price objective on West Pharmaceutical Services from $285.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, July 25th. Rothschild & Co Redburn began coverage on West Pharmaceutical Services in a research note on Monday, September 15th. They issued a “buy” rating and a $311.00 price objective on the stock. Finally, Evercore ISI set a $350.00 price objective on West Pharmaceutical Services in a research note on Tuesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $321.89.

West Pharmaceutical Services Trading Up 1.1%

West Pharmaceutical Services stock opened at $270.25 on Monday. The stock has a market cap of $19.43 billion, a P/E ratio of 40.46, a PEG ratio of 4.81 and a beta of 1.07. West Pharmaceutical Services, Inc. has a fifty-two week low of $187.43 and a fifty-two week high of $352.33. The firm’s fifty day moving average price is $254.94 and its 200-day moving average price is $231.51. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.08 and a current ratio of 2.78.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 24th. The medical instruments supplier reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.51 by $0.33. The firm had revenue of $766.50 million for the quarter, compared to analysts’ expectations of $725.11 million. West Pharmaceutical Services had a net margin of 16.48% and a return on equity of 18.43%. The business’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.52 earnings per share. West Pharmaceutical Services has set its FY 2025 guidance at 6.650-6.850 EPS. Equities research analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 19th. Investors of record on Wednesday, November 12th will be paid a $0.22 dividend. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, November 12th. West Pharmaceutical Services’s payout ratio is currently 12.57%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.